OPKOPKO Health, Inc.Signing up patients
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
CKD Stage 3 · CKD Stage 4 · Secondary Hyperparathyroidism · VDI
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Aug 5, 2026
- Main results expected
- Oct 2027
- Fully finished
- Aug 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Apparent clearance (CL/F)
Measured over: Up to 14 weeks
Volume of distribution (Vd/F)
Measured over: Up to 14 weeks
Terminal elimination half-life (t1/2)
Measured over: Up to 14 weeks
Incidence of treatment emergent adverse events (TEAE)
Measured over: Up to 14 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07494045 · record last updated 2026-08-20 · checked 2026-11-09 15:47 UTC